COCP Cocrystal Pharma Inc

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m. (noon) Eastern time (9:00 a.m. Pacific time). Investors and interested individuals can register for the conference . Questions from the audience during the live fireside chat will be welcomed.

Registered, qualified investors can request one-on-one meetings with Cocrystal management through the conference registration platform.

A video webcast of the presentation will be available within approximately 48 hours following the event on the Cocrystal , and as part of a complete catalog of presentations available on , the investor portal created by Noble. The webcast will be archived on the Company’s website and on Channelchek.com for 90 days following the event.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Contact:

Alliance Advisors IR

Jody Cain

310-691-7100

# # #



EN
28/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Depart...

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company’s President and co-CEO, will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures breakout ses...

 PRESS RELEASE

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrate...

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influe...

 PRESS RELEASE

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emergin...

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m. (noon) Eastern time (9:00 a.m. Pacific time). Investors and interested individuals can register for the conference . Questions from the audience during the live fireside chat will be welcomed. Registered, qual...

 PRESS RELEASE

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Prov...

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Our oral pan-viral protease inhibitor CDI-988 is a potential breakthrough first-i...

 PRESS RELEASE

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Pot...

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiviral activity against major norovirus variants including GII.4 and GII.17 strainsCompany reported favorable safety and tolerability of CDI-988 in Phase 1 and plans to initiate a human challenge study in 2025 for the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch